About: Cetuximab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cetuximab Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	Class
rdfs:label	Cetuximab
rdfs:subClassOf	Antibodies, Monoclonal nodeID://b658687 nodeID://b658688 nodeID://b658689
Has_Target	Receptor, Epidermal Growth Factor
Concept_In_Subset	FDA Established Names and Unique Ingredient Identifier Codes Terminology
Semantic_Type	Amino Acid, Peptide, or Protein Immunologic Factor
Preferred_Name	Cetuximab
NSC_Code	714692
UMLS_CUI	C0995188
CAS_Registry	205923-56-4
Accepted_Therapeutic_Use_For	Advanced colorectal cancer; Head and neck cancer
In_Clinical_Trial_For	Colorectal cancer; Fallopian Tube cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Head and Neck cancer; Cervical cancer; Hepatocellular cancer; Renal cell cancer
FDA_UNII_Code	PQX0D8J21J
Contributing_Source	FDA
ALT_DEFINITION	A monoclonal antibody used to treat certain types of head and neck cancer, and colorectal cancer that has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Erbitux binds to the epidermal growth factor receptor (EGFR), which is found on the surface of some types of cancer cells.NCI-GLOSS
PDQ_Open_Trial_Search_ID	42384
PDQ_Closed_Trial_Search_ID	42384
Legacy_Concept_Name	Cetuximab
FULL_SYN	Chimeric Monoclonal Antibody C225SYNCI CetuximabPTDCP50540 Chimeric Anti-EGFR Monoclonal AntibodySYNCI CETUXIMABPTFDAPQX0D8J21J Chimeric MoAb C225ABNCI ErbituxPTNCI-GLOSSCDR0000505985 ErbituxBRNCI IMC-C225CNNCI CetuximabPTNCI cetuximabPTNCI-GLOSSCDR0000045467
DEFINITION	A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.NCI
code	C1723
sameAs	CETUXIMAB CETUXIMAB
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0422675
is someValuesFrom of	nodeID://b650306 nodeID://b650308 nodeID://b656727 nodeID://b656730 nodeID://b658691 nodeID://b658693 nodeID://b658695 nodeID://b658699 nodeID://b658703 nodeID://b658706 nodeID://b658708 nodeID://b658710 nodeID://b659521 nodeID://b660506 nodeID://b672453 nodeID://b684361 nodeID://b693595
is sameAs of	CETUXIMAB CETUXIMAB CETUXIMAB

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 46 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software